Evaluation of switching low-dose inhaled corticosteroid to pranlukast for step-down therapy in well-controlled patients with mild persistent asthma

References

• Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and prevention. Available from: http://www.ginasthma.org/.2006
   Google Scholar
• Bateman ED, Jacques L, Goldfrad C, Atienza T, Mihaescu T, Duggan M. Asthma control can be maintained when fluticasone propionate/salmeterol in a single inhaler is stepped down. J Allergy Clin Immunol 2006;117:563–570
   PubMed Web of Science ®Google Scholar
• Fowler SJ, Currie GP, Lipworth BJ. Step-down therapy with low-dose fluticasone-salmeterol combination or medium-dose hydrofluoroalkane 134a-beclomethasone alone. J Allergy Clin Immunol 2002;109:929–935
   PubMed Web of Science ®Google Scholar
• Godard P, Greillier P, Pigearias B, Nachbaur G, Desfougeres JL, Attali V. Maintaining asthma control in persistent asthma: comparison of three strategies in a 6-month double-blind randomised study. Respir Med 2008;102:1124–1131
   PubMed Web of Science ®Google Scholar
• Hojo M, Mizutani T, Iikura M, Hirano S, Kobayashi N, Sugiyama H. Asthma control can be maintained after fixed-dose, budesonide/formoterol combination inhaler therapy is stepped down from medium to low dose. Allergol Int 2013;62:91–98
   PubMed Web of Science ®Google Scholar
• Reddel HK, Gibson PG, Peters MJ, Wark PA, Sand IB, Hoyos CM, Jenkins CR. Down-titration from high-dose combination therapy in asthma: removal of long-acting beta(2)-agonist. Respir Med 2010;104:1110–1120
   PubMed Web of Science ®Google Scholar
• Masoli M, Weatherall M, Beasley R. Fluticasone given once versus twice a day: meta-analysis. Respirology 2005;10:183–188
   PubMed Web of Science ®Google Scholar
• Masoli M, Weatherall M, Holt S, Beasley R. Budesonide once versus twice-daily administration: meta-analysis. Respirology 2004;9:528–534
   PubMed Web of Science ®Google Scholar
• Peters SP, Anthonisen N, Castro M, Holbrook JT, Irvin CG, Smith LJ, Wise RA. Randomized comparison of strategies for reducing treatment in mild persistent asthma. N Engl J Med 2007;356:2027–2039
   PubMed Web of Science ®Google Scholar
• Barnes N, Wei LX, Reiss TF, Leff JA, Shingo S, Yu C, Edelman JM. Analysis of montelukast in mild persistent asthmatic patients with near-normal lung function. Respir Med 2001;95:379–386
   PubMed Web of Science ®Google Scholar
• Malmstrom K, Rodriguez-Gomez G, Guerra J, Villaran C, Pineiro A, Wei LX, Seidenberg BC, Reiss TF. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial. Montelukast/Beclomethasone Study Group. Ann Intern Med 1999;130:487–495
   PubMed Web of Science ®Google Scholar
• Reiss TF, Chervinsky P, Dockhorn RJ, Shingo S, Seidenberg B, Edwards TB. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Montelukast Clinical Research Study Group. Arch Intern Med 1998;158:1213–1220
   PubMed Web of Science ®Google Scholar
• Price D, Musgrave SD, Shepstone L, Hillyer EV, Sims EJ, Gilbert RF, Juniper EF, et al. Leukotriene antagonists as first-line or add-on asthma-controller therapy. N Engl J Med 2011;364:1695–1707
   PubMed Web of Science ®Google Scholar
• Tamaoki J, Isono K, Taira M, Tagaya E, Nakata J, Kawatani K, Nagai A. Role of regular treatment with inhaled corticosteroid or leukotriene receptor antagonist in mild intermittent asthma. Allergy Asthma Proc 2008;29:189–196
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2006. Global strategy for diagnosis, management, and prevention of COPD. Available from: http://www.goldcopd.org/.2006
   Google Scholar
• Braido F, Baiardini I, Brandi S, Porcu A, Canonica GW. Allergic rhinitis and asthma ad hoc survey: clinical and psychological perspectives. Clin Exp Allergy 2007;37:788–793
   PubMed Web of Science ®Google Scholar
• Valovirta E, Pawankar R. Survey on the impact of comorbid allergic rhinitis in patients with asthma. BMC Pulm Med 2006;6:S3
   PubMedGoogle Scholar
• Ogawa Y, Calhoun WJ. The role of leukotrienes in airway inflammation. J Allergy Clin Immunol 2006;118:789–98; quiz 799–800
   PubMed Web of Science ®Google Scholar
• Bleecker ER, Welch MJ, Weinstein SF, Kalberg C, Johnson M, Edwards L, Rickard KA. Low-dose inhaled fluticasone propionate versus oral zafirlukast in the treatment of persistent asthma. J Allergy Clin Immunol 2000;105:1123–1129
   PubMed Web of Science ®Google Scholar
• Busse W, Raphael GD, Galant S, Kalberg C, Goode-Sellers S, Srebro S, Edwards L, Rickard K. Low-dose fluticasone propionate compared with montelukast for first-line treatment of persistent asthma: a randomized clinical trial. J Allergy Clin Immunol 2001;107:461–468
   PubMed Web of Science ®Google Scholar
• Meltzer EO, Lockey RF, Friedman BF, Kalberg C, Goode-Sellers S, Srebro S, Rickard K. Efficacy and safety of low-dose fluticasone propionate compared with montelukast for maintenance treatment of persistent asthma. Mayo Clin Proc 2002;77:437–445
   PubMed Web of Science ®Google Scholar
• Howarth PH, Redington AE, Springall DR, Martin U, Bloom SR, Polak JM, Holgate ST. Epithelially derived endothelin and nitric oxide in asthma. Int Arch Allergy Immunol 1995;107:228–230
   PubMed Web of Science ®Google Scholar
• Kanazawa H, Shoji S, Yamada M, Fujii T, Kawaguchi T, Kudoh S, Hirata K, Yoshikawa J. Increased levels of nitric oxide derivatives in induced sputum in patients with asthma. J Allergy Clin Immunol 1997;99:624–629
   PubMed Web of Science ®Google Scholar
• Kharitonov SA, Yates D, Robbins RA, Logan-Sinclair R, Shinebourne EA, Barnes PJ. Increased nitric oxide in exhaled air of asthmatic patients. Lancet 1994;343:133–135
   PubMed Web of Science ®Google Scholar
• Olin AC, Bake B, Toren K. Fraction of exhaled nitric oxide at 50 mL/s: reference values for adult lifelong never-smokers. Chest 2007;131:1852–1856
   PubMed Web of Science ®Google Scholar
• Smith AD, Cowan JO, Filsell S, McLachlan C, Monti-Sheehan G, Jackson P, Taylor DR. Diagnosing asthma: comparisons between exhaled nitric oxide measurements and conventional tests. Am J Respir Crit Care Med 2004;169:473–478
   PubMed Web of Science ®Google Scholar
• Dweik RA, Comhair SA, Gaston B, Thunnissen FB, Farver C, Thomassen MJ, Kavuru M, Hammel J. NO chemical events in the human airway during the immediate and late antigen-induced asthmatic response. Proc Natl Acad Sci USA 2001;98:2622–2627
   PubMed Web of Science ®Google Scholar
• Silkoff PE, McClean P, Spino M, Erlich L, Slutsky AS, Zamel N. Dose-response relationship and reproducibility of the fall in exhaled nitric oxide after inhaled beclomethasone dipropionate therapy in asthma patients. Chest 2001;119:1322–1328
   PubMed Web of Science ®Google Scholar
• Kharitonov SA, Yates DH, Barnes PJ. Inhaled glucocorticoids decrease nitric oxide in exhaled air of asthmatic patients. Am J Respir Crit Care Med 1996;153:454–457
   PubMed Web of Science ®Google Scholar
• Zietkowski Z, Bodzenta-Lukaszyk A, Tomasiak MM, Skiepko R, Szmitkowski M. Comparison of exhaled nitric oxide measurement with conventional tests in steroid-naive asthma patients. J Investig Allergol Clin Immunol 2006;16:239–246
   PubMed Web of Science ®Google Scholar
• Yamauchi K, Tanifuji Y, Pan LH, Yoshida T, Sakurai S, Goto S, Kuroda S, et al. Effects of pranlukast, a leukotriene receptor antagonist, on airway inflammation in mild asthmatics. J Asthma 2001;38:51–57
   PubMed Web of Science ®Google Scholar
• Bratton DL, Lanz MJ, Miyazawa N, White CW, Silkoff PE. Exhaled nitric oxide before and after montelukast sodium therapy in school-age children with chronic asthma: a preliminary study. Pediatr Pulmonol 1999;28:402–407
   PubMed Web of Science ®Google Scholar
• Sandrini A, Ferreira IM, Gutierrez C, Jardim JR, Zamel N, Chapman KR. Effect of montelukast on exhaled nitric oxide and nonvolatile markers of inflammation in mild asthma. Chest 2003;124:1334–1340
   PubMed Web of Science ®Google Scholar
• Bisgaard H, Loland L, Oj JA. NO in exhaled air of asthmatic children is reduced by the leukotriene receptor antagonist montelukast. Am J Respir Crit Care Med 1999;160:1227–1231
   PubMed Web of Science ®Google Scholar
• Ghiro L, Zanconato S, Rampon O, Piovan V, Pasquale MF, Baraldi E. Effect of montelukast added to inhaled corticosteroids on fractional exhaled nitric oxide in asthmatic children. Eur Respir J 2002;20:630–634
   PubMed Web of Science ®Google Scholar
• Shaw DE, Berry MA, Thomas M, Green RH, Brightling CE, Wardlaw AJ, Pavord ID. The use of exhaled nitric oxide to guide asthma management: a randomized controlled trial. Am J Respir Crit Care Med 2007;176:231–237
   PubMed Web of Science ®Google Scholar
• de Jongste JC, Carraro S, Hop WC, Baraldi E. Daily telemonitoring of exhaled nitric oxide and symptoms in the treatment of childhood asthma. Am J Respir Crit Care Med 2009;179:93–97
   PubMed Web of Science ®Google Scholar
• Pijnenburg MW, Bakker EM, Lever S, Hop WC, De Jongste JC. High fractional concentration of nitric oxide in exhaled air despite steroid treatment in asthmatic children. Clin Exp Allergy 2005;35:920–925
   PubMed Web of Science ®Google Scholar
• Smith AD, Cowan JO, Brassett KP, Herbison GP, Taylor DR. Use of exhaled nitric oxide measurements to guide treatment in chronic asthma. N Engl J Med 2005;352:2163–2173
   PubMed Web of Science ®Google Scholar
• Szefler SJ, Mitchell H, Sorkness CA, Gergen PJ, O'Connor GT, Morgan WJ, Kattan M. Management of asthma based on exhaled nitric oxide in addition to guideline-based treatment for inner-city adolescents and young adults: a randomised controlled trial. Lancet 2008;372:1065–1072
   PubMed Web of Science ®Google Scholar
• Pijnenburg MW, Hofhuis W, Hop WC, De Jongste JC. Exhaled nitric oxide predicts asthma relapse in children with clinical asthma remission. Thorax 2005;60:215–218
   PubMed Web of Science ®Google Scholar
• Dahlen SE, Dahlen B, Drazen JM. Asthma treatment guidelines meet the real world. N Engl J Med 2011;364:1769–1770
   PubMed Web of Science ®Google Scholar
• Dahlen SE. Treatment of asthma with antileukotrienes: first line or last resort therapy? Eur J Pharmacol 2006;533:40–56
   PubMed Web of Science ®Google Scholar
• Pedersen S, Agertoft L, Williams-Herman D, Kuznetsova O, Reiss TF, Knorr B, Dass SB, Wolthers OD. Placebo-controlled study of montelukast and budesonide on short-term growth in prepubertal asthmatic children. Pediatr Pulmonol 2007;42:838–843
   PubMed Web of Science ®Google Scholar